Vident Advisory LLC Sells 1,555 Shares of Novo Nordisk A/S (NYSE:NVO)

Vident Advisory LLC decreased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 3.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 41,461 shares of the company’s stock after selling 1,555 shares during the period. Vident Advisory LLC’s holdings in Novo Nordisk A/S were worth $3,567,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in NVO. Grassi Investment Management bought a new stake in Novo Nordisk A/S during the 4th quarter worth approximately $215,000. Merit Financial Group LLC grew its holdings in Novo Nordisk A/S by 121.4% during the 4th quarter. Merit Financial Group LLC now owns 19,240 shares of the company’s stock valued at $1,655,000 after buying an additional 10,550 shares in the last quarter. HB Wealth Management LLC grew its holdings in Novo Nordisk A/S by 5.4% during the 4th quarter. HB Wealth Management LLC now owns 17,122 shares of the company’s stock valued at $1,473,000 after buying an additional 875 shares in the last quarter. Ameritas Advisory Services LLC grew its holdings in Novo Nordisk A/S by 453.3% during the 4th quarter. Ameritas Advisory Services LLC now owns 11,000 shares of the company’s stock valued at $946,000 after buying an additional 9,012 shares in the last quarter. Finally, Annex Advisory Services LLC grew its holdings in Novo Nordisk A/S by 4.5% during the 4th quarter. Annex Advisory Services LLC now owns 5,052 shares of the company’s stock valued at $435,000 after buying an additional 219 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 1.7%

NYSE NVO opened at $68.17 on Wednesday. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The company has a fifty day moving average of $67.00 and a two-hundred day moving average of $83.76. The firm has a market capitalization of $305.91 billion, a price-to-earnings ratio of 20.72, a PEG ratio of 0.90 and a beta of 0.65. Novo Nordisk A/S has a 52 week low of $57.00 and a 52 week high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting the consensus estimate of $0.92. The company had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Hsbc Global Res raised shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, April 28th. Kepler Capital Markets raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. Stifel Nicolaus lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Guggenheim lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 17th. Finally, StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, April 25th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, five have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Moderate Buy” and an average target price of $135.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.